With a diverse experience in treating fertility patients, Dr. Vaughan has a keen interest in Polycystic Ovarian Syndrome (PCOS) and complex fertility issues, alongside a focus on fertility preservation. His primary research revolves around sperm quality and tackling male factor infertility.
Originally from Cork, Ireland, Dr. Vaughan's academic journey began with a full scholarship at The Royal College of Surgeons in Dublin, graduating with high honors. A former competitive rugby player, he completed his OBGYN training in some of Dublin's most prestigious hospitals, where he led significant research projects.
His move to Boston marked a continuation of his impressive career. Dr. Vaughan excelled during his residency at Tufts Medical Center, receiving multiple awards and research grants. His fellowship at Boston IVF and Beth Israel Deaconess Medical Center/Harvard Medical School further solidified his reputation, earning numerous grants and accolades.
A Clinical Instructor at Harvard Medical School, Dr. Vaughan is double board-certified in both Reproductive Endocrinology and Infertility and Obstetrics and Gynecology. His contributions to over 70 peer-reviewed manuscripts and his commitment to evidence-based treatment approaches make him an invaluable asset to our team.
Her research focuses on how environmental exposures across natural, built and social settings impact fertility, pregnancy and child health across the reproductive lifespan.
Professor Messerlian is at the forefront of reshaping reproductive medicine by championing a dyadic approach: engaging both male and female partners in fertility care and prevention. As the founder of Vie Science, she brings this vision into the digital space, leveraging big data and AI to personalize fertility interventions for couples, with the goal of addressing global fertility challenges at scale.
She is a NIH-funded investigator, a public health advocate, and a prolific scholar, with over 100 publications spanning scientific papers, book chapters, and commentaries. In addition to her academic appointments at Harvard University, Massachusetts General Hospital, and McGill University, she serves on the U.S. Environmental Protection Agency (EPA) Scientific Advisory Board, where she contributes to national policy efforts to reduce exposure to harmful reproductive toxins.
Through her work, Professor Messerlian continues to drive innovation in fertility care and environmental health, while mentoring the next generation of public health leaders.
He earned his undergraduate degree from Rice University and his medical degree from Yale School of Medicine. Prof. Eisenberg completed his urology residency at the University of California, San Francisco, and a fellowship in Male Reproductive Medicine and Microsurgery at Baylor College of Medicine in Texas.
Currently, he leads the Male Reproductive Medicine and Surgery Program at Stanford. He is an editorial editor for the Fertility & Sterility, an associate editor for Andrology, and serves on several editorial boards, and is an active international speaker and prolific author. His research primarily focuses on the connections between male health and fertility, including studies on how impaired sperm production affects overall health and strategies for enhancing testosterone and sperm production.
Recently, Prof. Eisenberg was a guest on Andrew Huberman’s podcast, HubermanLabs, where he shed light on the role of sperm quality to overall men’s health. This episode provides actionable information on men’s sexual health and highlights the importance of prevention in reproductive health.
Her extensive research covers urology, male infertility, and prostate cancer, and she has authored over 512 publications with more than 15,000 citations.
Dr. Lamb was one of the main authors in developing the World Health Organization (WHO) sperm testing guidelines, American Urological Association (AUA) and American Society for Reproductive Medicine (ASRM) guidelines for diagnosing and treating male infertility. These guidelines advocate for comprehensive evaluations and customized treatments.
Her research has also advanced understanding of the genetic factors that impact sperm function and male reproductive health. Dr. Lamb's leadership in research and guideline development solidifies her status as a preeminent authority in reproductive medicine.
Dr. Lazarou is an Active Staff Member at Mass General Brigham Newton-Wellesley Hospital, Beth Israel Lahey Health, New England Baptist Hospital, and works in conjunction with Massachusetts General Hospital. He also works closely with fertility groups in New England and throughout the country to provide optimal care to men and their partners.
Dr. Lazarou specializes in treating all aspects of sexual and reproductive medicine. His expertise includes vasectomies and reversals, severe male factor infertility as well as fertility preservation for men with cancer. He also treats men with low testosterone symptoms and sexual dysfunction. He is also one of the few urologists in the U.S. trained in advanced microsurgery of the male reproductive system.
Furthermore, Dr. Lazarou lectures nationally and internationally on various topics in male reproductive and sexual medicine before medical and patient groups. He has published several medical articles and co-authored a book chapter on the effect of advancing age on male reproduction.
Dr. Lazarou belongs to numerous professional organizations such as the American Urological Association, the Sexual Medicine Society of North America, the American Society of Reproductive Medicine, the New England Fertility Society, and the Society for the Study of Male Reproduction.
Dr. Lazarou has been listed as one of Boston Magazine's Top Docs for the years 2020, 2021, 2022, 2023, 2024 and 2025.
Dr. Collins’ research explores the convergence of genomics, proteomics, transcriptomics, metabolomics, and bioinformatics to investigate tumor progression and therapy resistance. His laboratory develops and applies integrative approaches to analyze high-dimensional datasets, with the goal of improving cancer diagnostics and therapeutic strategies.
He holds adjunct academic appointments at the University of California, San Francisco’s Helen Diller Family Comprehensive Cancer Center and serves as a visiting scientist at the Lawrence Berkeley National Laboratory. Dr. Collins has previously held research positions at both Lawrence Livermore and Lawrence Berkeley National Laboratories, contributing to the advancement of cancer systems biology.
Dr. Collins was instrumental in the development of End Sequence Profiling (ESP), a pioneering method that laid the foundation for modern paired-end sequencing. His research with the UCSF Prostate SPORE has led to the identification of DNA-based biomarkers that may predict progression and metastasis in prostate cancer patients. He continues to lead efforts integrating array-based and next-generation sequencing technologies to enable large-scale tumor genome profiling and accessible, personalized oncology.
In addition to his academic work, Dr. Collins serves on several scientific advisory boards, including Genome British Columbia’s Molecular Lymphoma project and Combimatrix Molecular Diagnostics. He is also on the organizing committee for the Advances in Genome Biology and Technology (AGBT) conference and holds editorial responsibilities with the Open Pathology Journal. His work has resulted in over 80 peer-reviewed publications, multiple patents, and numerous awards, including the Cornelius L. Hopper Scientific Achievement Award for Innovation from the California Cancer Research Program.
A recipient of the Medal of Honor – the United States’ highest military decoration – Lt. Col. Swenson is recognized for his heroic actions during the 2009 Battle of Ganjgal in Afghanistan, where he repeatedly risked his life to evacuate wounded soldiers and Afghan allies under intense enemy fire. His leadership and valor reflect the highest standards of service in the U.S. Army.
He graduated from Seattle University and received his commission as an officer in the United States Army, where he served with distinction across multiple deployments. Lt. Col. Swenson’s military career has been marked by exemplary leadership, strategic command, and operational expertise in high-stakes environments.
Following his active-duty service, Lt. Col. Swenson has remained deeply engaged in national defense and technology innovation. He works closely with venture firms and dual-use technology companies, focusing on aligning cutting-edge commercial solutions with mission-critical government needs. His current role with Context Ventures, a firm investing in deep tech and national security-focused companies, positions him at the forefront of defense innovation.
Lt. Col. Swenson continues to serve the public interest by shaping how emerging technologies support both national security and global stability. He is a frequent advisor to policymakers and innovators working across defense, government and the private sector.
His experience provides a unique strategic advantage in navigating government partnerships and dual-use pathways through agencies such as the Department of Defense (DoD) and DARPA.
He is currently CEO of Vista AI, Inc, where he is leading the development of AI software to automate and standardize MRI scanning enabling faster, more consistent image acquisition and lowering dependence on highly specialized operators.
Previously, Daniel founded Shockwave Medical (NASDAQ: SWAV), inventing Intravascular Lithotripsy (IVL), leading the company from inception to early commercialization setting the stage for rapid growth and the transition to a publicly listed leader in cardiovascular intervention. He also co-founded Calibra Medical, acquired by Johnson & Johnson, and founded Avail Medsystems, enabling real-time expert participation in the operating room.
Earlier in his career, Daniel was the first non-technical hire at Intuitive Surgical where he helped set the specs, and establish the initial market, for the da Vinci surgical robot during the company’s formative years.
Across his career, Daniel has repeatedly taken clinically novel technologies from invention through to commercialization. He is a named inventor on more than 140 patents and applications. He holds an MBA from Stanford Graduate School of Business and a BS in Economics from The Wharton School of the University of Pennsylvania.
Earlier in his career, Joseph was part of CombinatoRx and Owkin, where he helped pioneer the use of multimodal patient data and machine learning to uncover new disease subtypes. Before moving into life sciences, he spent his first career in astrophysics at Harvard, Cambridge, and MIT, studying gravitational lensing and developing computational models for complex systems.
He currently advises a portfolio of biotech startups, incubators, and venture funds and is co-founding companies building expert foundation models for the life sciences. Joseph’s work focuses on applying LLM-powered generative AI to accelerate precision medicine.
He is also passionate about startups and participating in accelerators and Incubators within the Cambridge / Boston community.
Oscar holds a PhD in Biomedical Engineering and has conducted AI research in industry and academia, including at MIT and Duke. Collectively, Oscar’s research has produced 130+ articles and presentations in top-tier journals (Nature Medicine, Nature Comms) as well as technical and clinical conferences. Oscar’s experience includes AI/ML (computer vision, generative AI, foundational models) in biopharma R&D and diagnostics across multiple diseases (ONC, IMM, CVM, ophthalmology).
Schodin has co‑founded and been actively involved in companies addressing unmet medical needs in kidney disease and diagnostics, including Nephraegis Therapeutics, a pharmaceutical development company focused on preventing and treating acute kidney injury (AKI), and NephAlert/KidneySentinel, which develop tools for early detection and monitoring of kidney injury.
He has also served as Chief Operating Officer of OpComm, Inc., a company that provides software solutions to improve perioperative workflow efficiency for surgical teams in hospitals and academic medical centers. At Nephraegis Therapeutics, Schodin has played a legal and strategic role, guiding early corporate development alongside leadership focused on kidney disease therapeutics.
His professional experience spans molecular biology research, legal practice in biotechnology and pharmaceutical law, executive leadership in medical and startup environments, and strategic advising in healthcare innovation. This multidisciplinary background positions him at the intersection of science, law, and business, enabling him to advance novel biomedical solutions.
Brian’s passion has been to develop innovative emerging technology as a CTO and founder. At an early age, Brian built and launched wilsonsleather.com, turning it into a multi-million-dollar online business. He authored two patents on e-commerce technology, which were showcased at MIT. Brian has managed development teams for brands such as BestBuy.com, Harry Winston, and 1-800 Flowers. Brian has also been involved in several big data projects, including one with UnitedHealth Group.
Brian has been involved in founding several professional organizations. He founded the NYC chapter of The Machine Learning Society, one of New York City’s largest AI/ML professional organizations. While at Columbia University, he co-founded the Columbia Blockchain Alliance.
Brian is a frequent guest lecturer at Columbia University on blockchain, fintech, IoT, and AI. In addition to his lecturing, he is a public speaker, including policy talks in Washington DC at the Capital, Senate, and Chamber of Commerce. He contributed to the Token Taxonomy Act of 2018 (H.R.7356). He speaks frequently for JP Morgan and other banking industry conferences such as Nacha ACH on the impacts of AI.Brian has a B.A. in Economics from Denison University and a M.S. in Technology Management from Columbia University.
David has successfully scaled teams to over 1,000 employees across multiple countries; directly created and managed ARR up to $600M and enabled ARR exceeding $10B through the deployment of hyper-scale platforms supporting the enterprise and federal/defense markets.
David has successfully led or been involved in over 50 M&A transactions, 2 IPOs and managed multiple turnarounds from startups to F100 enterprises. His expertise extends to financial and corporate structures, including recapitalizations, carve-outs and IP licensing.
David’s technical expertise encompasses solutioning from design concept and startup, to refactoring and hyper-scaling platforms. He holds patents in hardware, firmware, data center, AI/ML, Cyber and Cloud.
Notable companies David led include Acer, Phoenix, Connect, Active, Ensim, Ingram Micro and Globe Newswire. David is also actively involved in advising numerous medical science foundations.
Dr. Webster's career spans a diverse range of roles across academia, start-ups, SMEs, and technical consultancies. His expertise bridges multiple industries, including biomedical, automotive, aeronautical, and petrochemical sectors. He has held positions such as numerical simulation specialist, academic group leader, business development manager, and technical project manager, working at the interface of mechanics, electronics, photonics, software, biology, and chemistry. This interdisciplinary background has enabled him to contribute unique perspectives to successful system design and product development.
At ZHAW, Dr. Webster leads the development and commercial translation of next-generation medical diagnostic systems. He is responsible for identifying and managing R&D projects with industrial collaborators, focusing on translating basic scientific research into commercial applications, particularly in in-vitro medical diagnostics.
Prior to his current role, Dr. Webster contributed to the successful commercialization of a digital PCR point-of-care device at Volpi Group and led business development and product innovation at Scanco Medical.
Dr. Webster is an INCOSE Certified Systems Engineering Professional and is fluent in English, German, and French. His professional achievements include securing funding from the Swiss National Science Foundation and the European Union, as well as delivering products to market within short timeframes.
Dr. Komorowski’s academic journey includes a Doctor of Medicine from Université de Lille 2, a Master of Research (MRes) in Bioengineering (with Distinction), and a PhD in Medicine and Bioengineering from Imperial College London. He has also completed advanced training in aerospace, mountain, diving, and hyperbaric medicine, and has held research and clinical fellowships at the European Space Agency and NASA.
His research is focused on the application of Machine Learning and AI to critical care, particularly in developing advanced decision support systems. Dr. Komorowski is the lead developer of the "AI Clinician," a reinforcement learning model designed to optimize treatment strategies for sepsis in intensive care. His work also addresses the safety assurance of AI-based clinical decision support tools, aiming to ensure their reliability and safety prior to clinical deployment.
Komorowski has been a visiting scholar at the Massachusetts Institute of Technology (MIT), contributing to projects involving the secondary analysis of healthcare records at the Laboratory of Computational Physiology.
He has taught and co-instructed courses such as "Reinforcement Learning for Healthcare" at Harvard University, and has received multiple honors, including the Imperial College PhD Scholarship and the Royal Society of Medicine’s Research and Innovation First Prize in Emergency Medicine.
Dr. Komorowski is an active member of several professional organizations, including the UK Space Biomedicine Association, the Society of Critical Care Medicine and the European Society of Intensive Care Medicine.
.jpeg)
